233 related articles for article (PubMed ID: 22102607)
1. Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.
Dvorak CC; Fisher BT; Sung L; Steinbach WJ; Nieder M; Alexander S; Zaoutis TE
Pediatr Blood Cancer; 2012 Jul; 59(1):21-6. PubMed ID: 22102607
[TBL] [Abstract][Full Text] [Related]
2. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.
Pechlivanoglou P; Le HH; Daenen S; Snowden JA; Postma MJ
J Antimicrob Chemother; 2014 Jan; 69(1):1-11. PubMed ID: 23975736
[TBL] [Abstract][Full Text] [Related]
3. Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.
Vicenzi EB; Calore E; Decembrino N; Berger M; Perruccio K; Carraro F; Rossin S; Putti MC; Molinaro M; Tridello G; Cesaro S
Eur J Haematol; 2018 Mar; 100(3):315-322. PubMed ID: 29240266
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
Winston DJ; Bartoni K; Territo MC; Schiller GJ
Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
[TBL] [Abstract][Full Text] [Related]
5. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
Maertens J
Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
[TBL] [Abstract][Full Text] [Related]
6. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
[TBL] [Abstract][Full Text] [Related]
7. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
8. The role of primary antifungal prophylaxis in patients with haematological malignancies.
Pagano L; Caira M
Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():19-26. PubMed ID: 24372659
[TBL] [Abstract][Full Text] [Related]
9. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation.
Hiramatsu Y; Maeda Y; Fujii N; Saito T; Nawa Y; Hara M; Yano T; Asakura S; Sunami K; Tabayashi T; Miyata A; Matsuoka KI; Shinagawa K; Ikeda K; Matsuo K; Tanimoto M;
Int J Hematol; 2008 Dec; 88(5):588-595. PubMed ID: 19039629
[TBL] [Abstract][Full Text] [Related]
10. Is Posaconazole Really Effective in Adolescent patients as a Prophylactic Agent: Experience of a Tertiary Care Center.
Arikan K; Aytac S; Büyükcam A; Cengiz AB; Cetinkaya FD; Cetin M; Ozsurekci Y; Ceyhan M; Kara A
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e613-e618. PubMed ID: 33560081
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study.
Shen Y; Huang XJ; Wang JX; Jin J; Hu JD; Yu K; Wu DP; Wang SJ; Yu L; Chen XQ; Liu T; Liang YM; Chen FP; Li Y; Shen ZX
Int J Clin Pharmacol Ther; 2013 Sep; 51(9):738-45. PubMed ID: 23924680
[TBL] [Abstract][Full Text] [Related]
12. Antifungal prophylaxis and treatment in patients with hematological malignancies.
Hwang YY; Liang R
Expert Rev Anti Infect Ther; 2010 Apr; 8(4):397-404. PubMed ID: 20377335
[TBL] [Abstract][Full Text] [Related]
13. Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis.
Ping B; Zhu Y; Gao Y; Yue C; Wu B
Ann Hematol; 2013 Jun; 92(6):831-9. PubMed ID: 23455400
[TBL] [Abstract][Full Text] [Related]
14. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
Salavert M; Jarque I
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
[TBL] [Abstract][Full Text] [Related]
15. [Prophylaxis of fungal infections in haematological patients: contra].
Schwartz S
Dtsch Med Wochenschr; 2010 Sep; 135(38):1871. PubMed ID: 20842608
[No Abstract] [Full Text] [Related]
16. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
17. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment?
Cherif H; Kalin M; Björkholm M
Eur J Haematol; 2006 Oct; 77(4):288-92. PubMed ID: 16856930
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
[TBL] [Abstract][Full Text] [Related]
19. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis.
Kaya Z; Gursel T; Kocak U; Aral YZ; Kalkanci A; Albayrak M
Pediatr Blood Cancer; 2009 Apr; 52(4):470-5. PubMed ID: 19058205
[TBL] [Abstract][Full Text] [Related]
20. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
